# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ann Richards (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML019-SYN-TD
- Date: 1997-02-10
- Fictional facility: St. Posthumous Health Center
- Fictional author: Rosalind Teague, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## What we are working on

- She does not want to break bones and lose her posture the way her mother did **S**
- She wants to keep traveling and speaking without slowing down, and wants a plan she can keep on the road **S**

## Your goals

- Total calcium intake of about 1200 mg a day, mostly from food, by the four-week visit. Target: 1997-03-10. Recorded outcome: About 1200 mg a day from food by her own three-day food record. **S**
- 25-hydroxyvitamin D of 30 ng/mL or more before the first infusion. Target: 1997-05-12. Recorded outcome: 24 ng/mL at intake and 38 ng/mL at three months. **S**
- First zoledronic acid dose by the three-month visit, with normal calcium and kidney function and a dental check done. Target: 1997-05-12. Recorded outcome: Given at three months after normal calcium (9.5 mg/dL) and eGFR (81) and a routine dental examination. **S**
- Complete the eight-week balance and strength program, with no falls through six months. Target: 1997-08-11. Recorded outcome: 16 of 16 sessions; Timed Up and Go 9 seconds and tandem stance 20 seconds at six months; no falls. **S**
- Serum CTX at least 30 percent lower three months after the first dose. Target: 1997-08-11. Recorded outcome: 560 pg/mL at baseline and 190 pg/mL at three months after the dose (66 percent lower). **S**
- Sustained remission from alcohol use disorder throughout the episode. Target: 1997-08-11. Recorded outcome: No alcohol reported at any visit; AUDIT-C 0 at intake. **S**

## What we agreed to do

- Endocrinology consultation to confirm the diagnostic category from the T-scores and FRAX, the risk category, the choice of drug, the secondary-causes work-up, and the plan for monitoring and treatment duration. Guideline: CMID: Clinical Monitoring Intelligence Database, osteoporosis monograph (2026); The clinician's guide to prevention and treatment of osteoporosis (2022); American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis, 2020 Update (2020); Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline (2019) **S**
- Drug treatment, because FRAX is above the treatment thresholds, with the agent confirmed at the endocrinology visit: zoledronic acid 5 mg intravenously once a year, given only after 25-hydroxyvitamin D is 30 ng/mL or more, calcium is normal, eGFR is above 35, and a routine dental examination is done; acetaminophen for the expected aches and fever after the first dose; reassess after three yearly doses for a drug holiday. Guideline: CMID: Clinical Monitoring Intelligence Database, osteoporosis monograph (2026); The clinician's guide to prevention and treatment of osteoporosis (2022); American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis, 2020 Update (2020); Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline (2019); Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update (2020) **S**
- Calcium about 1200 mg a day in total, from food first, and vitamin D3 1971 units a day to reach 30 ng/mL or more, then continue; caffeine kept to two cups of coffee a day; no tobacco or alcohol. Guideline: CMID: Clinical Monitoring Intelligence Database, osteoporosis monograph (2026); The clinician's guide to prevention and treatment of osteoporosis (2022); American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis, 2020 Update (2020) **S**
- Falls prevention by CDC STEADI: supervised balance and strength exercise with a physical therapist for eight weeks, then a home program three times a week; weight-bearing exercise most days; home safety review (stair rails, night lights, no loose rugs); low-heeled shoes when traveling; yearly vision check. Guideline: The clinician's guide to prevention and treatment of osteoporosis (2022); Falls Prevention in Community-Dwelling Older Adults: Interventions (2024); STEADI: Stopping Elderly Accidents, Deaths, and Injuries (2026) **S**
- Monitoring on the CMID osteoporosis schedule: secondary-causes tests at baseline (calcium, albumin, phosphate, magnesium, alkaline phosphatase, creatinine and eGFR, PTH, 25-hydroxyvitamin D, TSH, blood count, and 24-hour urine calcium); calcium and creatinine before each infusion; fasting CTX at baseline and three to six months after starting; 25-hydroxyvitamin D after repletion and then yearly; height and fall-risk screen yearly; FRAX recalculated when risk factors change; DXA of the spine and hip two years after starting, on the same scanner. Guideline: CMID: Clinical Monitoring Intelligence Database, osteoporosis monograph (2026); American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis, 2020 Update (2020); Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline (2019); Osteoporosis to Prevent Fractures: Screening (2025) **S**
- Recovery-oriented care for alcohol use disorder in sustained remission: ask about alcohol, cravings, and stress at each visit in a non-judgmental way, support the recovery practices she uses, avoid sedating medicines, and review safety with the 988 Suicide & Crisis Lifeline at each visit. Guideline: CMID: Clinical Monitoring Intelligence Database, osteoporosis monograph (2026); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024) **S**

## Follow-up

- 1997-02-10: New patient visit for bone health after a fall with a hand fracture **S**
- 1997-03-10: Four-week bone health review with endocrinology consultation **S**
- 1997-05-12: Three-month bone health review and first zoledronic acid infusion **S**
- 1997-08-11: Six-month bone health review, three months after the first infusion **S**
- 1997-10-06: Adult preventive visit **S**

This teaching document does not replace care from a qualified clinician.
